Epidermal Expression of Filaggrin/Profilaggrin Is Decreased in Atopic Dermatitis: Reverse Association With Mast Cell Tryptase and IL-6 but Not With Clinical Severity
Restricted accessResearch articleFirst published online December, 2015
Epidermal Expression of Filaggrin/Profilaggrin Is Decreased in Atopic Dermatitis: Reverse Association With Mast Cell Tryptase and IL-6 but Not With Clinical Severity
A decrease in filaggrin expression contributes to the pathogenesis of atopic dermatitis (AD) and can be modified by inflammatory factors.
Objectives
The aim of this study was to determine the correlation of (pro)filaggrin (filaggrin and profilaggrin) expression with clinical severity in AD and with mast cell (MC) tryptase, chymase, and IL-6.
Methods
Punch biopsies were collected from 17 patients with moderate-to-severe AD and from 10 psoriatic patients. Atopic dermatitis severity was measured using different clinical parameters. (Pro)filaggrin, MC tryptase, chymase, and IL-6 were stained using immunohistochemical, enzymehistochemical, and sequential double-staining methods.
Results
(Pro)filaggrin expression was lower in the lesional than in the nonlesional granular layer in AD and was correlated negatively with itch severity but not with other severity parameters. (Pro)filaggrin expression was also decreased in the psoriatic lesions. In AD, (pro)filaggrin expression correlated negatively with the number of tryptase+ MCs in the nonlesional granular layer and with IL-6+ MCs in both the nonlesional and lesional granular layers.
Conclusion
(Pro)filaggrin expression is decreased in AD and is reversely associated with MC tryptase and IL-6. However, it does not associate with disease severity, and it was also decreased in psoriasis.
Get full access to this article
View all access options for this article.
References
1.
ProkschE, BrandnerJM, JensenJM. The skin: an indispensable barrier. Exp Dermatol, 2008; 17: 1063–1072.
2.
KawasakiH, KuboA, SasakiT, et al.Loss-of-function mutations within the filaggrin gene and atopic dermatitis. Curr Probl Dermatol, 2011; 41: 35–46.
3.
HowellMD, KimBE, GaoP, et al.Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol, 2007; 120: 150–155.
4.
HvidM, VestergaardC, KempK, et al.IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction?. J Invest Dermatol, 2011; 131: 150–157.
5.
CornelissenC, MarquardtY, CzajaK, et al.IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol, 2012; 129: 426–433, 433.e1-8.
6.
Gutowska-OwsiakD, SchauppAL, SalimiM, et al.IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol, 2012; 21: 104–110.
7.
Gutowska-OwsiakD, SchauppAL, SalimiM, et al.Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br J Dermatol, 2011; 165: 492–498.
8.
EnokssonM, LybergK, Möller-WesterbergC, et al.Mast cells as sensors of cell injury through IL-33 recognition. J Immunol, 2011; 186: 2523–2528.
9.
EdwardsMJ. Therapy directed against thymic stromal lymphopoietin. Drug News Perspect, 2008; 21: 312–316.
10.
SoterNA. Morphology of atopic eczema. Allergy, 1989; 44(suppl 9): 16–19.
11.
JärvikallioA, NaukkarinenA, HarvimaIT, et al.Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br J Dermatol, 1997; 136: 871–877.
12.
WeidnerN, AustenKF. Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Pathol Res Pract, 1993; 189: 156–162.
13.
HarvimaIT, NilssonG. Mast cells as regulators of skin inflammation and immunity. Acta Derm Venereol, 2011; 91: 644–650.
14.
GschwandtnerM, MildnerM, MlitzV, et al.Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy, 2013; 68: 37–47.
15.
WeidingerS, RümmlerL, KloppN, et al.Association study of mast cell chymase polymorphisms with atopy. Allergy, 2005; 60: 1256–1261.
16.
MaoXQ, ShirakawaT, YoshikawaT, et al.Association between genetic variants of mast-cell chymase and eczema. Lancet, 1996; 348: 581–583.
17.
WatanabeN, TomimoriY, TerakawaM, et al.Oral administration of chymase inhibitor improves dermatitis in NC/Nga mice. J Invest Dermatol, 2007; 127: 971–973.
18.
IlvesT, HarvimaIT. Decrease in chymase activity is associated with increase in IL-6 expression in mast cells in atopic dermatitis. Acta Derm Venereol, 2015; 95: 411–416.
19.
SteinhoffM, BuddenkotteJ, ShpacovitchV, et al.Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev, 2005; 26: 1–43.
20.
SteinhoffM, CorveraCU, ThomaMS, et al.Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol, 1999; 8: 282–294.
21.
KyoyaM, KawakamiT, SomaY. Serum thymus and activation-regulated chemokine (TARC) and interleukin-31 levels as biomarkers for monitoring in adult atopic dermatitis. J Dermatol Sci, 2014; 75: 204–207.
22.
TsujiiK, AndohT, UiH, et al.Involvement of tryptase and proteinase-activated receptor-2 in spontaneous itch-associated response in mice with atopy-like dermatitis. J Pharmacol Sci, 2009; 109: 388–395.
23.
LeeJS, KimIS, RyuJS, et al.House dust mite, Dermatophagoides pteronissinus increases expression of MCP-1, IL-6, and IL-8 in human monocytic THP-1 cells. Cytokine, 2008; 42: 365–371.
24.
RibbingC, EngblomC, LappalainenJ, et al.Mast cells generated from patients with atopic eczema have enhanced levels of granule mediators and an impaired Dectin-1 expression. Allergy, 2011; 66: 110–119.
25.
WangXP, SchunckM, KallenKJ, et al.The interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis. J Invest Dermatol, 2004; 123: 124–131.
26.
Esparza-GordilloJ, SchaarschmidtH, LiangL, et al.A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis. J Allergy Clin Immunol, 2013; 132: 371–377.
27.
IlvesT, HarvimaIT. OX40 ligand and OX40 are increased in atopic dermatitis lesions but do not correlate with clinical severity. J Eur Acad Dermatol Venereol, 2013; 27: e197–e205.
28.
RajkaG, LangelandT. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh), 1989; 144: 13–14.
29.
HongboY, ThomasCL, HarrisonMA, et al.Translating the science of quality of life into practice: what do dermatology life quality index scores mean?. J Invest Dermatol, 2005; 125: 659–664.
30.
SaarinenJV, HarvimaRJ, NaukkarinenA, et al.The release of histamine is associated with the inactivation of mast cell chymase during immediate allergic wheal reaction in the skin. Clin Exp Allergy, 2001; 31: 593–601.
31.
PanulaHE, HyttinenMM, ArokoskiJP, et al.Articular cartilage superficial zone collagen birefringence reduced and cartilage thickness increased before surface fibrillation in experimental osteoarthritis. Ann Rheum Dis, 1998; 57: 237–245.
32.
HendersonJ, NorthstoneK, LeeSP, et al.The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. J Allergy Clin Immunol, 2008; 121: 872–877 e9.
33.
BrownSJ, IrvineAD. Atopic eczema and the filaggrin story. Semin Cutan Med Surg, 2008; 27: 128–137.
34.
MorarN, Willis-OwenSA, MoffattMF, et al.The genetics of atopic dermatitis. J Allergy Clin Immunol, 2006; 118: 24–34 quiz 35–6.
35.
CorkMJ, DanbySG, VasilopoulosY, et al.Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol, 2009; 129: 1892–1908.
36.
MarsellaR. Does filaggrin expression correlate with severity of clinical signs in dogs with atopic dermatitis?. Vet Dermatol, 2013; 24: 266-e59.
37.
YosipovitchG. Dry skin and impairment of barrier function associated with itch—new insights. Int J Cosmet Sci, 2004; 26: 1–7.
38.
PellerinL, HenryJ, HsuCY, et al.Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol, 2013; 131: 1094–1102.
39.
WatanabeS, WagatsumaK, IchikawaE, et al.Abnormal distribution of epidermal protein antigens in psoriatic epidermis. J Dermatol, 1991; 18: 143–151.
40.
GerritsenMJ, ElbersME, de JongEM, et al.Recruitment of cycling epidermal cells and expression of filaggrin, involucrin and tenascin in the margin of the active psoriatic plaque, in the uninvolved skin of psoriatic patients and in the normal healthy skin. J Dermatol Sci, 1997; 14: 179–188.
41.
ChangYC, WuWM, ChenCH, et al.Association between P478S polymorphism of the filaggrin gene and risk of psoriasis in a Chinese population in Taiwan. Arch Dermatol Res, 2008; 300: 133–137.
42.
ThyssenJP, JohansenJD, CarlsenBC, et al.The filaggrin null genotypes R501X and 2282del4 seem not to be associated with psoriasis: results from general population study and meta-analysis. J Eur Acad Dermatol Venereol, 2012; 26: 782–784.
43.
LeeSE, JeongSK, LeeSH. Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis. Yonsei Med J, 2010; 51: 808–822.
44.
HachemJP, HoubenE, CrumrineD, et al.Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol, 2006; 126: 2074–2086.
45.
DemerjianM, HachemJP, TschachlerE, et al.Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the protease-activated receptor type 2. Am J Pathol, 2008; 172: 86–97.
46.
HorsmanheimoL, HarvimaIT, JärvikallioA, et al.Mast cells are one major source of interleukin-4 in atopic dermatitis. Br J Dermatol, 1994; 131: 348–353.
47.
LinAM, RubinCJ, KhandpurR, et al.Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol, 2011; 187: 490–500.
48.
SonED, KimHJ, ParkT, et al.Staphylococcus aureus inhibits terminal differentiation of normal human keratinocytes by stimulating interleukin-6 secretion. J Dermatol Sci, 2014; 74: 64–71.
